Edwards Lifesciences Co. (NYSE:EW) Stock Holdings Trimmed by Altium Capital Management LLC

Altium Capital Management LLC reduced its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 25.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 165,000 shares of the medical research company's stock after selling 57,000 shares during the quarter. Edwards Lifesciences comprises approximately 3.5% of Altium Capital Management LLC's holdings, making the stock its 7th largest holding. Altium Capital Management LLC's holdings in Edwards Lifesciences were worth $12,215,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Virtu Financial LLC purchased a new stake in shares of Edwards Lifesciences in the third quarter valued at $3,173,000. World Investment Advisors LLC lifted its stake in Edwards Lifesciences by 1,660.7% in the third quarter. World Investment Advisors LLC now owns 72,277 shares of the medical research company's stock worth $4,770,000 after purchasing an additional 68,172 shares during the last quarter. Wilmington Savings Fund Society FSB grew its stake in shares of Edwards Lifesciences by 147.0% during the third quarter. Wilmington Savings Fund Society FSB now owns 9,106 shares of the medical research company's stock valued at $601,000 after buying an additional 5,420 shares during the last quarter. Destination Wealth Management lifted its stake in shares of Edwards Lifesciences by 2.8% during the 3rd quarter. Destination Wealth Management now owns 7,012 shares of the medical research company's stock worth $463,000 after acquiring an additional 193 shares during the last quarter. Finally, Tidal Investments LLC boosted its holdings in Edwards Lifesciences by 0.7% during the 3rd quarter. Tidal Investments LLC now owns 39,532 shares of the medical research company's stock valued at $2,609,000 after acquiring an additional 275 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 6,164 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the transaction, the chief executive officer now directly owns 59,083 shares in the company, valued at approximately $4,106,859.33. This represents a 9.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Steven R. Loranger sold 5,739 shares of Edwards Lifesciences stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the sale, the director now owns 60,372 shares in the company, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,853 shares of company stock worth $5,163,062 in the last three months. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Performance

NYSE EW traded down $2.30 on Monday, reaching $69.23. 3,546,323 shares of the company's stock traded hands, compared to its average volume of 4,629,837. The stock has a 50 day moving average price of $71.31 and a 200-day moving average price of $70.92. The firm has a market cap of $40.70 billion, a price-to-earnings ratio of 9.93, a P/E/G ratio of 4.82 and a beta of 1.15. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Equities research analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on EW shares. Barclays upped their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Royal Bank of Canada reissued an "outperform" rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Morgan Stanley increased their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 12th. Canaccord Genuity Group upped their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a "hold" rating in a research note on Thursday, February 13th. Finally, Truist Financial reduced their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a report on Friday, April 11th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $78.55.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.